Wies Deckers
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Wies Deckers has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Christophe M. Deroose
Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, Katholieke Universiteit Leuven, 3000 Leuven, Belgium
3 shared publications - Karolien Goffin
Department of Imaging and Pathology, Nuclear Medicine and Molecular Imaging, KU Louvain, Leuven Brain Institute, Leuven, Belgium
2 shared publications - Koen Van Laere
Department of Imaging and Pathology, Nuclear Medicine and Molecular Imaging, KU Leuven, Leuven, Belgium
2 shared publications - Michel Koole
Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium
2 shared publications - Alexander Giesen
KU Leuven 4 Leuven
1 shared publication - Ann Mertens
UZ Leuven
1 shared publication
Latest Publications
- 17 February 2026
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 53 (6) , 3999-4014
Meningioma theranostics: a retrospective analysis of somatostatin receptor PET/CT imaging and peptide receptor radionuclide therapy
Purpose This study aims to evaluate differences in PET/CT imaging of meningioma using both gallium-68- and fluorine-18-labelled somatostatin receptor (SSTR) tracers, to characterize incidentally detected meningiomas on SSTR PET/CT, and to analyse institutional experience with Peptide Receptor Radionuclide Therapy (PRRT) in meningioma. Methods This single centre retrospective study included all SSTR PET/CT scans of meningioma patients (2007-2024) performed with [68Ga]Ga-DOTATOC, [68Ga]Ga-DOTATATE or [18F]AlF-NOTA-octreotide. For lesions ≥ 1cm3, tumour uptake was quantified using three distinct delineation methods: an absolute SUV threshold of 2.3, a relative threshold of 1.73 × SUVpeak of a meningeal reference region, and a relative threshold of 11% of the lesion’s SUVmax. Tumour-to-background ratios were calculated. Meningioma patients treated with PRRT were identified from our institutional registry (2016-2024). Results Of 4,136 SSTR PET/CTs, 152 patients with 171 SSTR-expressing meningiomas were included. Incidental meningiomas were found in 3.7% of patients imaged for unrelated indications. Quantitative analysis of 86 lesions (≥ 1 cm3) showed robust uptake for [18F]AlF-NOTA-octreotide (n = 7), [68Ga]Ga-DOTATATE (n = 73), and [68Ga]Ga-DOTATOC (n = 6), without significant between-tracer differences across delineation strategies. All tracers demonstrated high tumour‐to‐meningeal uptake ratios with ratios ranging from 51 to 146 for [18F]AlF-NOTA-octreotide, 10-329 for [68Ga]Ga-DOTATATE, and 12-76 for [68Ga]Ga-DOTATOC, confirming excellent tumour-to-background contrast. Among 12 heavily pretreated patients receiving PRRT, disease control rate was 50%, median progression-free survival 8 months, and overall survival 20 months. Conclusion SSTR PET/CT enables high-contrast meningioma visualisation. [18F]AlF-NOTA-octreotide seems clinically interchangeable with gallium-68-labelled tracers, while offering logistical advantages. PRRT achieves meaningful disease stabilisation, supporting further validation in prospective randomised studies.
- 17 February 2026
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 53 (6) , 3999-4014
Meningioma theranostics: a retrospective analysis of somatostatin receptor PET/CT imaging and peptide receptor radionuclide therapy
Purpose This study aims to evaluate differences in PET/CT imaging of meningioma using both gallium-68- and fluorine-18-labelled somatostatin receptor (SSTR) tracers, to characterize incidentally detected meningiomas on SSTR PET/CT, and to analyse institutional experience with Peptide Receptor Radionuclide Therapy (PRRT) in meningioma. Methods This single centre retrospective study included all SSTR PET/CT scans of meningioma patients (2007-2024) performed with [68Ga]Ga-DOTATOC, [68Ga]Ga-DOTATATE or [18F]AlF-NOTA-octreotide. For lesions ≥ 1cm3, tumour uptake was quantified using three distinct delineation methods: an absolute SUV threshold of 2.3, a relative threshold of 1.73 × SUVpeak of a meningeal reference region, and a relative threshold of 11% of the lesion’s SUVmax. Tumour-to-background ratios were calculated. Meningioma patients treated with PRRT were identified from our institutional registry (2016-2024). Results Of 4,136 SSTR PET/CTs, 152 patients with 171 SSTR-expressing meningiomas were included. Incidental meningiomas were found in 3.7% of patients imaged for unrelated indications. Quantitative analysis of 86 lesions (≥ 1 cm3) showed robust uptake for [18F]AlF-NOTA-octreotide (n = 7), [68Ga]Ga-DOTATATE (n = 73), and [68Ga]Ga-DOTATOC (n = 6), without significant between-tracer differences across delineation strategies. All tracers demonstrated high tumour‐to‐meningeal uptake ratios with ratios ranging from 51 to 146 for [18F]AlF-NOTA-octreotide, 10-329 for [68Ga]Ga-DOTATATE, and 12-76 for [68Ga]Ga-DOTATOC, confirming excellent tumour-to-background contrast. Among 12 heavily pretreated patients receiving PRRT, disease control rate was 50%, median progression-free survival 8 months, and overall survival 20 months. Conclusion SSTR PET/CT enables high-contrast meningioma visualisation. [18F]AlF-NOTA-octreotide seems clinically interchangeable with gallium-68-labelled tracers, while offering logistical advantages. PRRT achieves meaningful disease stabilisation, supporting further validation in prospective randomised studies.
- 4 November 2024
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 52 (1) , 109-112
Combined brain and spinal FDG PET in the differentiation between ALS and ALS mimics – correction and additional validation study
- 4 November 2024
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 52 (1) , 109-112
Combined brain and spinal FDG PET in the differentiation between ALS and ALS mimics – correction and additional validation study
- 13 September 2024
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 52 (2) , 766-778
Comparison of PSMA immunohistochemistry scoring systems to parametric [18F]PSMA-1007 PET/MRI in primary prostate cancer
Purpose Quantification of PSMA expression via PSMA PET is well-established, however quantification of PSMA via immunohistochemistry (IHC) is not standardized. Our aim was to determine the most optimal PSMA IHC scoring system to quantify PSMA expression with PSMA PET as reference standard. Methods Primary intermediate- and high-risk prostate cancer patients received an [18F]PSMA-1007 PET/MRI followed by radical prostatectomy. SUVmax, SUVmean and Ki of the prostate tumor was determined. Prostate tumors were stained with anti-PSMA antibodies and scored by 2 readers via 10 IHC scoring systems: histochemical score (H-score), immunoreactivity scorepredominant intensity (IRSpredominant intensity), IRS classificationpredominant intensity, IRSmean intensity, IRS classificationmean intensity, Allred score, predominant expression pattern, Shannon diversity index (SDI), percentage negatively stained cells and total percentage positively stained cells. Spearman’s rank correlation coefficients (ρ) were calculated between PET parameters and IHC scoring systems. Interreader agreement for the IHC scoring systems was measured by the intraclass correlation coefficient (ICC). Results Fifty tumors in 46 patients were analysed. H-score had the best correlation with SUVmax (ρ 0.615 p < 0.0001) and SUVmean (ρ 0.570, p < 0.0001) and the second best correlation with Ki (ρ 0.411, p = 0.0030). SDI had the best correlation with Ki (ρ -0.440, p = 0.0014) and the second best correlation with SUVmax (ρ -0.516, p = 0.0001) and SUVmean (ρ -0.490, p = 0.0003). A moderate interreader agreement was observed for H-score (ICC 0.663, 95% CI 0.495–0.797) and SDI (ICC 0.546, 95% CI 0.354–0.725). Conclusion H-score had the best correlation with PSMA PET quantification and an acceptable interreader agreement. Therefore, we deem H-score the most optimal PSMA IHC scoring system.
- 13 September 2024
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 52 (2) , 766-778
Comparison of PSMA immunohistochemistry scoring systems to parametric [18F]PSMA-1007 PET/MRI in primary prostate cancer
Purpose Quantification of PSMA expression via PSMA PET is well-established, however quantification of PSMA via immunohistochemistry (IHC) is not standardized. Our aim was to determine the most optimal PSMA IHC scoring system to quantify PSMA expression with PSMA PET as reference standard. Methods Primary intermediate- and high-risk prostate cancer patients received an [18F]PSMA-1007 PET/MRI followed by radical prostatectomy. SUVmax, SUVmean and Ki of the prostate tumor was determined. Prostate tumors were stained with anti-PSMA antibodies and scored by 2 readers via 10 IHC scoring systems: histochemical score (H-score), immunoreactivity scorepredominant intensity (IRSpredominant intensity), IRS classificationpredominant intensity, IRSmean intensity, IRS classificationmean intensity, Allred score, predominant expression pattern, Shannon diversity index (SDI), percentage negatively stained cells and total percentage positively stained cells. Spearman’s rank correlation coefficients (ρ) were calculated between PET parameters and IHC scoring systems. Interreader agreement for the IHC scoring systems was measured by the intraclass correlation coefficient (ICC). Results Fifty tumors in 46 patients were analysed. H-score had the best correlation with SUVmax (ρ 0.615 p < 0.0001) and SUVmean (ρ 0.570, p < 0.0001) and the second best correlation with Ki (ρ 0.411, p = 0.0030). SDI had the best correlation with Ki (ρ -0.440, p = 0.0014) and the second best correlation with SUVmax (ρ -0.516, p = 0.0001) and SUVmean (ρ -0.490, p = 0.0003). A moderate interreader agreement was observed for H-score (ICC 0.663, 95% CI 0.495–0.797) and SDI (ICC 0.546, 95% CI 0.354–0.725). Conclusion H-score had the best correlation with PSMA PET quantification and an acceptable interreader agreement. Therefore, we deem H-score the most optimal PSMA IHC scoring system.
- Open Access
- 1 January 2022
- Published by Elsevier in SSRN Electronic Journal
Effect of Sleeve Gastrectomy and Roux-En-Y Gastric Bypass on Gastrointestinal Physiology
Background: Knowledge regarding the gastrointestinal physiology after sleeve gastrectomy and Roux-en-Y gastric bypass is urgently needed to understand, prevent and treat the nutritional and pharmacological complications of bariatric surgery.Aim: To investigate the effect of sleeve gastrectomy and Roux-en-Y gastric bypass on gastrointestinal motility (e.g., transit and pressure), pH, and intestinal bile acid concentration.Material and methods: An exploratory cross-sectional study was performed in six participants living with obesity, six participants who underwent sleeve gastrectomy, and six participants who underwent Roux-en-Y gastric bypass. During the first visit, a wireless motility capsule (SmartPill ©) was ingested after an overnight fast to measure gastrointestinal transit, pH, and pressure. During the second visit, a gastric emptying scintigraphy test of a nutritional drink labeled with 99m Tc-colloid by a dual-head SPECT gamma camera was performed to measure gastric emptying half-time (GET 1/2). During the third visit, two customized multiple lumen aspiration catheters were positioned to collect fasting and postprandial intestinal fluids to measure bile acid concentration.Results: Immediate pouch emptying (P =0.0007) and a trend for faster GET 1/2 (P =0.09) were observed in both bariatric groups. There was a tendency for a shorter orocecal transit in participants with sleeve gastrectomy and Roux-en-Y gastric bypass (P =0.08). The orocecal segment was characterized by a higher 25th percentile pH (P =0.004) and a trend for a higher median pH in both bariatric groups (P =0.07). Fasting total bile acid concentration was 7.5-fold higher in the common limb after Roux-en-Y gastric bypass (P <0.0001) and 3.5-fold higher in the jejunum after sleeve gastrectomy (P =0.009) compared to obesity. Postprandial bile acid concentration was 3-fold higher in the jejunum after sleeve gastrectomy (P =0.0004) and 6.5-fold higher in the common limb after Roux-en-Y gastric bypass (P <0.0001) compared to obesity.Conclusion: The anatomical alterations of sleeve gastrectomy and Roux-en-Y gastric bypass have an important impact on gastrointestinal physiology. This data confirms changes in transit and pH and provides the first evidence for altered intraluminal bile acid concentration.
- 1 January 2022
- Published by Elsevier in SSRN Electronic Journal
Open AccessEffect of Sleeve Gastrectomy and Roux-En-Y Gastric Bypass on Gastrointestinal Physiology
Background: Knowledge regarding the gastrointestinal physiology after sleeve gastrectomy and Roux-en-Y gastric bypass is urgently needed to understand, prevent and treat the nutritional and pharmacological complications of bariatric surgery.Aim: To investigate the effect of sleeve gastrectomy and Roux-en-Y gastric bypass on gastrointestinal motility (e.g., transit and pressure), pH, and intestinal bile acid concentration.Material and methods: An exploratory cross-sectional study was performed in six participants living with obesity, six participants who underwent sleeve gastrectomy, and six participants who underwent Roux-en-Y gastric bypass. During the first visit, a wireless motility capsule (SmartPill ©) was ingested after an overnight fast to measure gastrointestinal transit, pH, and pressure. During the second visit, a gastric emptying scintigraphy test of a nutritional drink labeled with 99m Tc-colloid by a dual-head SPECT gamma camera was performed to measure gastric emptying half-time (GET 1/2). During the third visit, two customized multiple lumen aspiration catheters were positioned to collect fasting and postprandial intestinal fluids to measure bile acid concentration.Results: Immediate pouch emptying (P =0.0007) and a trend for faster GET 1/2 (P =0.09) were observed in both bariatric groups. There was a tendency for a shorter orocecal transit in participants with sleeve gastrectomy and Roux-en-Y gastric bypass (P =0.08). The orocecal segment was characterized by a higher 25th percentile pH (P =0.004) and a trend for a higher median pH in both bariatric groups (P =0.07). Fasting total bile acid concentration was 7.5-fold higher in the common limb after Roux-en-Y gastric bypass (P <0.0001) and 3.5-fold higher in the jejunum after sleeve gastrectomy (P =0.009) compared to obesity. Postprandial bile acid concentration was 3-fold higher in the jejunum after sleeve gastrectomy (P =0.0004) and 6.5-fold higher in the common limb after Roux-en-Y gastric bypass (P <0.0001) compared to obesity.Conclusion: The anatomical alterations of sleeve gastrectomy and Roux-en-Y gastric bypass have an important impact on gastrointestinal physiology. This data confirms changes in transit and pH and provides the first evidence for altered intraluminal bile acid concentration.